Report Overview:
HPV infectionscaninfect thegenitalareasof menincludingtheskinonandaroundthepenisoranus. Theseinfectionscanalso bespreadto themoutHandthethroat. EvenwhenHPV infectionsarepersistent to themalepopulationandcancauseseverediseasessucHasgenitalwarts, analcancers, penilecancers, andcancersof theoropharynx, thereiscurrentlyno HPV test recommendformen. Theapprovedtestsavailableinthemarket areforscreeningwomenforcervicalcancers. Theyarenot usefulforthescreeningof HPVrelatedcancersorgenitalwartsinmen.
This report provides a deep insight into the global Human Papillomavirus (HPV) Testing market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Human Papillomavirus (HPV) Testing market size was estimated at USD 757 million in 2024 and is projected to reach USD 1215.24 million by 2032, exhibiting a CAGR of 5.40% during the forecast period. CAGR of 5.40% (2025 – 2032)
By Types:
• Pap Smear Test • HPV DNA Test
By Applications: Diagnostic Centers Hospitals
Key players include:
• Roche
• Agilent Technologies
• Becton
• DickinsonandCompany
• QiagenN.V.
• Thermo FisherScientificInc.
• Abbott Laboratories
• Including or Excluding key companies relevant to your analysis.
